Gastrointestinal Stromal Tumors
📧 Sign up to get email alerts when something new happens for Gastrointestinal Stromal Tumors.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2023-10-19EMA Withdrawn: Imatinib Koanaa (imatinib mesilate) — Koanaa Healthcare GmbH
The EMA status shows Imatinib Koanaa (imatinib mesilate) has been withdrawn from the market by Koanaa Healthcare GmbH.
-
EMA withdrawal · 2018-10-09EMA Withdrawn: Imatinib Teva B.V. (imatinib mesilate) — Teva B.V.
EMA withdrew the Imatinib Teva B.V. product (imatinib mesilate) from the market.
-
CLINICAL_TRIALS withdrawal · 2017-10-12Clinical Trial Update: SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor) [Phase 2]
Phase 2 trial SARC029 evaluating trametinib plus pazopanib in Gastrointestinal Stromal Tumor has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2016-12-09Clinical Trial Update: Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST)
The clinical trial NCT02488746 evaluating endoscopic full thickness resection of gastric subepithelial tumors (FROST) has been terminated.
-
CLINICAL_TRIALS withdrawal · 2016-08-16Clinical Trial Update: Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)
The Bayer-managed access program for regorafenib in gastrointestinal stromal tumors (GIST) that progressed after standard therapy is no long…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2015-08-04Clinical Trial Update: Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors [Phase 1]
A Phase 1 trial evaluating dovitinib in combination with imatinib for gastrointestinal stromal tumors has been withdrawn.